Supplementary information from A Combinatorial Strategy for Targeting &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt;-Mutant Cancers with BRAF&lt;sup&gt;V600E&lt;/sup&gt; Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)